Jose Masdeu
Neurology · Bethesda, MDNPI 1376853770
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,380 of the $55,619 with a category attached, or 67.2%. Lilly USA, LLC accounts for 73.9% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $27,959, more than ten times the $595 reported in 2019. Among neurology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $257.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$41K
- Biogen$6K
- Eli Lilly$3K
- GE HealthCare$3K
- Eisai Inc.$233
- Acadia Pharmaceuticals Inc$218
- plus $2K from 31 others
Across 197 payments — averaging $29,499 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- Biogen$1.4M
- AbbVie$872K
- Eisai Inc.$787K
- Novartis$105K
- Acadia Pharmaceuticals Inc$12K
- plus $11K from 2 others
What the payments were for
- Consulting fees$10,85220%
- Speaking & faculty fees$37,38067%
- Travel & lodging$2,8325%
- Food & beverage$4,5568%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 59 | $41,130 |
| Biogen | 24 | $6,148 |
| Eli Lilly | 2 | $3,287 |
| GE HealthCare | 7 | $2,560 |
| Eisai Inc. | 10 | $233 |
| Acadia Pharmaceuticals Inc | 14 | $218 |
| CSL Behring | 9 | $193 |
| Otsuka America Pharmaceutical, Inc. | 8 | $164 |
| Avanir Pharmaceuticals, Inc. | 10 | $149 |
| AbbVie | 7 | $125 |
| Siemens Medical Solutions USA, Inc. | 1 | $113 |
| Amgen | 8 | $110 |
| Fujirebio Diagnostics, Incorporated | 2 | $108 |
| Merz North America, Inc. | 6 | $104 |
| Sanofi | 6 | $98 |
| Amneal Pharmaceuticals LLC | 1 | $95 |
| Genentech, Inc. | 3 | $85 |
| Corium, LLC | 3 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Lundbeck LLC | 3 | $59 |
| AstraZeneca | 2 | $46 |
| Novartis | 3 | $45 |
| Grifols USA, LLC | 3 | $42 |
| Neurocrine Biosciences, Inc. | 3 | $42 |
| Tanabe Pharma America, Inc. | 3 | $35 |
| Catalyst Pharmaceuticals, Inc. | 2 | $30 |
| C2n Diagnostics, LLC | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Amylyx Pharmaceuticals, Inc. | 1 | $26 |
| Life Molecular Imaging Ltd | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Argenx US, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$12,097
How this compares
$55,619 in reported general payments places this provider in the 90th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $185,279 |
| Rivastigmine | 38 | $8,123 |
| Memantine Hcl | 145 | $5,426 |
| Donepezil Hcl | 388 | $4,574 |
| Divalproex Sodium | 46 | $1,529 |
| Quetiapine Fumarate | 84 | $1,462 |
| Ziprasidone Hcl | 16 | $713 |
| Olanzapine | 15 | $538 |
| Trazodone Hcl | 45 | $473 |
| Escitalopram Oxalate | 41 | $361 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 25 | $313 |
| Gabapentin | 11 | $120 |
| Pregabalin | 12 | $50 |
| Sertraline Hcl | 11 | $36 |
| Alprazolam | 15 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $42 | $185,27924 claims |
| Lilly USA, LLCOlanzapine | $41,130 | $53815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 neurology providers in Maryland.
Other neurology in Bethesda
- Pavel KleinBethesda$709K
- Wilson BryanBethesda$42K
- Daniel BeckerLutherville$1.6M
- Sangjin OhGlen Burnie$1.5M
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- David CornblathLutherville$345K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Bruce RabinLutherville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.